Loading stock data…
NTLA
$12.89-0.60 (-4.45%)
Market ClosedLast close Jun 9
Intellia Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Intellia Therapeutics, Inc. in the Healthcare sector is trading at $12.89 with a market capitalization of $1.8B. Wall Street consensus targets $26.63 (19 analysts), implying a +106.6% move over the next 12 months. The stock is currently 54% below its 52-week high of $28.25, remaining 3.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +106.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$12.89
Potential Downside
0%
Whystock Fair Value$12.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Buy
Mean target$26.63+106.6%
Range$8.00 – $95.00
Fundamentals
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.47%
Volume
Today's trading volume
5.62M
Recent News
Exploring 3 High Growth Tech Stocks in the US Market
Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that exhibit strong innovation potential and robust financial health to capitalize on future opportunities.
Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 13, H.C. Wainwright reiterated Intellia Therapeutics (NASDAQ:NTLA) as a Buy but lowered the price target to $25 from $30. The price target cut is in response to a recent share offering expected to result in significant […]
Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update
Intellia Therapeutics Inc. (NASDAQ:NTLA) is one of the 9 Stocks Crushing the Market With Surging Returns. Intellia Therapeutics snapped a three-day losing streak on Thursday, soaring 13.29 percent to close at $14.75 apiece, as investors positioned portfolios ahead of the phase 3 results of its lonvo-z study in hereditary angioedema (HAE). In a notice on […]
High Growth Tech Stocks To Watch In US June 2026
The United States market has recently seen a 1.2% increase over the past week and an impressive 27% rise over the last year, with earnings expected to grow by 17% annually. In this thriving environment, identifying high-growth tech stocks involves focusing on companies with strong innovation potential and scalability that align well with these positive market trends.
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.